CRISPR Activation Unlocks Splicing Variant Analysis in Easily Accessible Human Cells

Study Background and Research Question

Genetic variants that disrupt mRNA splicing are a significant and often underappreciated cause of hereditary disorders, especially those involving the nervous system. However, studying the functional consequences of such variants is challenging because many disease-associated genes are not expressed in accessible cell types, such as skin fibroblasts. This limitation restricts the use of RNA diagnostics in the clinical assessment of splice-altering mutations, leading to diagnostic uncertainty for approximately 20% of Mendelian disease genes (source: Terkelsen et al., 2024).

The core research question addressed by Terkelsen et al. is whether CRISPR activation (CRISPRa) can be harnessed to induce the expression of such genes in accessible primary cells, thereby enabling the direct analysis of splicing outcomes for pathogenic variants within their native genomic context.

Key Innovation from the Reference Study

The central innovation is an RNA-based CRISPRa platform utilizing dCas9-VPR delivered as mRNA, which transiently and robustly upregulates target gene expression in primary skin fibroblasts. This enables the detection and characterization of splicing patterns for genes such as MPZ (myelin protein zero) and SPAST (spastin), which are typically silent or minimally expressed outside their tissue of origin (source: Terkelsen et al., 2024).

The approach represents a technically accessible, scalable method for diagnostic laboratories to functionally assess splicing variants detected by DNA sequencing, overcoming longstanding barriers due to tissue-specific gene expression.

Methods and Experimental Design Insights

The study utilized a dCas9-VPR fusion protein, with VPR representing a tripartite activator (VP64-p65-Rta), and single-guide RNAs (sgRNAs) targeting regions immediately upstream of the transcription start site (TSS) of selected genes. The components were delivered by mRNA transfection to minimize genomic integration risk and optimize temporal control of gene induction. Skin fibroblasts from individuals with suspected monogenic neurological disorders were cultured and transfected with the CRISPRa system targeting either MPZ or SPAST.

Following overnight incubation, total RNA was extracted and subjected to reverse transcription polymerase chain reaction (RT-PCR), next-generation sequencing (NGS), and long-read sequencing to profile splicing isoforms and detect aberrant transcript variants. The protocol is compatible with standard diagnostic laboratory workflows.

Protocol Parameters

• assay | CRISPRa mRNA transfection | skin fibroblasts | enables transient, high-fidelity gene induction | paper
• assay | sgRNA design targeting -300 bp to TSS | gene-specific | maximizes transcriptional activation efficiency | paper
• assay | overnight (16–24 h) incubation post-transfection | skin fibroblasts | yields robust mRNA upregulation | paper
• assay | RT-PCR, NGS, long-read sequencing | induced fibroblast RNA | enables comprehensive splice isoform detection | paper
• assay | Use of modified nucleosides (e.g., N1-Methylpseudouridine) in mRNA | any mammalian cell line | enhances translation, reduces immunogenicity | workflow_recommendation

Core Findings and Why They Matter

Terkelsen et al. demonstrated that CRISPRa induced marked upregulation of both MPZ and SPAST in primary fibroblasts, as confirmed by RT-PCR and sequencing. Most importantly, this facilitated the detection and quantification of both normal and aberrant splice isoforms arising from patient-derived variants. For instance, specific MPZ variants were shown to produce exon-skipping events or cryptic splice site usage, with direct implications for molecular diagnosis (source: Terkelsen et al., 2024).

This method enables the functional validation of variants of uncertain significance (VUS) affecting splicing, which is critical for genetic counseling and clinical decision-making. By using easily accessible cell types and avoiding the need for invasive tissue biopsies, the workflow is highly scalable and suitable for routine diagnostic applications.

Comparison with Existing Internal Articles

Several recent reviews and application notes have highlighted the utility of modified nucleosides, such as N1-Methylpseudouridine, in enhancing mRNA translation and minimizing innate immune activation in cell-based assays:

• "N1-Methylpseudouridine: Next-Gen mRNA Modification for Enhanced Translation" explores the mechanisms by which this modified nucleoside improves translation efficiency and immune tolerance, which are relevant for mRNA-based CRISPRa delivery systems.
• "N1-Methylpseudouridine: Empowering Next-Gen mRNA Therapeutics" discusses high-fidelity gene activation and rare disease modeling, closely aligning with the diagnostic objectives of the Terkelsen et al. study.

While these internal articles provide a mechanistic and translational context for nucleoside modification, the present study stands out by directly applying mRNA-based CRISPRa for functional diagnostics in primary human cells, bridging the gap between molecular innovation and clinical utility.

Limitations and Transferability

Despite its strong proof-of-principle, several limitations remain. First, the CRISPRa approach is currently optimized for genes with well-characterized TSS regions and may require assay redesign for complex loci. Additionally, while the protocol is suitable for fibroblasts, transferability to other easily accessible cell types (e.g., blood-derived cells) will require further validation. The reliance on efficient mRNA delivery and translation also introduces potential variability, which can be mitigated by adopting optimized mRNA chemistries (e.g., with N1-Methylpseudouridine) for future protocol refinement (workflow_recommendation).

Clinical interpretation of detected splice variants still relies on expert curation and integration with patient phenotype data. The method is not designed to assess splicing consequences in a tissue-specific regulatory context, so findings must be interpreted with consideration of possible differences in splicing machinery between fibroblasts and the relevant disease tissue.

Research Support Resources

Researchers aiming to apply CRISPRa-based splicing assays in primary cells may benefit from using chemically modified nucleosides to improve mRNA translation, reduce immunogenicity, and increase assay reproducibility. N1-Methylpseudouridine (SKU B8340, APExBIO) is a validated modified nucleoside that supports high-efficiency mRNA delivery in mammalian systems, as recommended for similar workflows. Incorporating this reagent can help optimize the fidelity and yield of CRISPRa-induced gene expression, thereby facilitating robust splicing analysis in diagnostic and research settings (workflow_recommendation).